Pharmaceutical News

RSS

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Clavis Pharma ASA, the clinical stage oncology focused pharmaceutical company, and Clovis Oncology, Inc., the newly formed oncology company led by former Pharmion Corporation executives, announced today an agreement for the further development and commercialisation of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.

24 Nov 2009

Iowa State University's researcher develops and ships H1N1 vaccine for swine producers

The only swine vaccine available for the H1N1 virus has been sent to vaccinate a swine herd infected with the virus. The vaccination marks the first time vaccine has been sent to a swine herd diagnosed with the pandemic flu.

24 Nov 2009

Clavis Pharma announces $380 million agreement to develop its CP-4126 drug candidate

Clavis Pharma ASA, the clinical stage oncology focused pharmaceutical company, announced today a $380 million agreement for the further development and commercialisation of its drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.

24 Nov 2009

New technology developed to rapidly identify compounds for the treatment of heart failure

Research conducted by University of Minnesota scientists, in collaboration with Celladon Corporation, has led to the invention of technology to more rapidly identify compounds for the treatment of heart failure.

24 Nov 2009

Breast cancer patients treated with chemotherapy drug Taxol more likely to develop chronic neuropathic pain

Breast cancer patients treated with the chemotherapy drug Taxol (paclitaxel) are more likely to develop chronic neuropathic pain, according to research published in The Journal of Pain, the peer review publication of the American Pain Society.

24 Nov 2009

Lysteda tablets to treat menorrhagia approved by the FDA

The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.

24 Nov 2009

Treatment rates for hepatitis C virus declining, say researchers

Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007.

24 Nov 2009

PX’Therapeutics sets up additional biomanufacturing unit

PX’Therapeutics SA (formerly known as Protein’eXpert) announces the set up of an additional biomanufacturing unit dedicated to the production of therapeutic proteins and monoclonal antibodies in mammalian cells.

24 Nov 2009

Neuromed discusses Exalgo NDA application with the FDA

Covidien today announced that on November 13, 2009, representatives of Neuromed discussed the pending New Drug Application (NDA) for the product candidate ExalgoTM (hydromorphone HCl extended release) tablets with staff from the United States Food and Drug Administration (FDA). Mallinckrodt Inc., a Covidien company, obtained the commercial rights to Exalgo in the United States from Neuromed Development Inc., a subsidiary of Neuromed Pharmaceuticals Ltd., in June 2009.

24 Nov 2009

DTCA linked with increased Medicaid pharmacy expenditures

Direct-to-consumer advertising (DTCA) for a commonly prescribed antiplatelet drug does not appear associated with increased use, but may be associated with increased drug costs and Medicaid pharmacy expenditures, according to a report in the November 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

24 Nov 2009

Jubilant Organosys, UAB and Southern Research Institute announce joint venture to accelerate global drug development

Jubilant Organosys, the University of Alabama at Birmingham (UAB), and Southern Research Institute today announced a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases. It is a unique U.S.-India arbitraged and leveraged partnership that will accelerate the development of affordable therapies for patients worldwide.

24 Nov 2009

AmKor and Hengdian Group sign license agreement to develop and market new drug candidate in China

AmKor (AmKor Pharma, Inc.) and Hengdian Group (Hengdian Group Ltd) today announced the signing of licensing agreement for further development and commercialization of Neu2000 in China.

24 Nov 2009

10 x '20 Initiative calls for global commitment to develop 10 new antibiotics by 2020

The Infectious Diseases Society of America (IDSA) has asked for a commitment from the Obama administration and the European Union to further the Society's mission to achieve the development of 10 new antibiotics within the next 10 years, known as the 10 x '20 Initiative. The World Health Organization (WHO) has identified antimicrobial resistance as one of the three greatest threats to human health.

24 Nov 2009

AP/News-Observer examines state of vaccine research

The Associated Press/News-Observer examines revitalized vaccine research, including for such conditions as malaria, TB and HIV. "Vaccines are no longer a sleepy, low-profit niche in a booming drug industry.

23 Nov 2009

Alleged HIPAA violations by CVS Caremark, again

The National Community Pharmacists Association (NCPA), Consumer Action, U.S. Public Interest Research Group (PIRG), Patient Privacy Rights, Private Citizen, and Privacy Journal are asking the U.S. Department of Health and Human Services’ Office for Civil Rights (OCR) and the Federal Trade Commission to investigate potentially illegal activity by CVS Caremark.

23 Nov 2009

BioTrends Research Group releases Wave 2 report on AMAG's Feraheme

BioTrends Research Group, Inc. released Wave 2 of its LaunchTrends(TM): Feraheme report, the second in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15.

23 Nov 2009

Walgreens re-launches its website with expanded shopping tools and services

Walgreens, the nation’s largest drugstore chain and a leading destination for health and wellness services, today announced the re-launch of Walgreens.com (www.walgreens.com), offering users a variety of new healthy living and product resources, along with expanded yet simplified shopping tools and services.

23 Nov 2009

Caldolor Injection effective in treating fever in hospitalized burn patients

Cumberland Pharmaceuticals Inc. today announced positive new top-line results from a study evaluating the safety and efficacy of Caldolor (ibuprofen) Injection in treating fever in hospitalized burn patients.

23 Nov 2009

FDA grants Fast Track designation for ARCA biopharma's Gencaro

ARCA biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of GencaroTM, the Company’s investigational, pharmacologically unique beta-blocker and mild vasodilator, for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population.

23 Nov 2009

Texas Court dismisses all claims against Merck in VIOXX-related lawsuit

Merck said today that Travis County, Texas District Court Judge Scott H. Jenkins granted Merck's motion for summary judgment, dismissing all claims in a VIOXX-related lawsuit filed on behalf of the State of Texas.

23 Nov 2009

Pharmaceutical News

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Iowa State University's researcher develops and ships H1N1 vaccine for swine producers

Clavis Pharma announces $380 million agreement to develop its CP-4126 drug candidate

New technology developed to rapidly identify compounds for the treatment of heart failure

Breast cancer patients treated with chemotherapy drug Taxol more likely to develop chronic neuropathic pain

Lysteda tablets to treat menorrhagia approved by the FDA

Treatment rates for hepatitis C virus declining, say researchers

PX’Therapeutics sets up additional biomanufacturing unit

Neuromed discusses Exalgo NDA application with the FDA

DTCA linked with increased Medicaid pharmacy expenditures

Jubilant Organosys, UAB and Southern Research Institute announce joint venture to accelerate global drug development

AmKor and Hengdian Group sign license agreement to develop and market new drug candidate in China

10 x '20 Initiative calls for global commitment to develop 10 new antibiotics by 2020

AP/News-Observer examines state of vaccine research

Alleged HIPAA violations by CVS Caremark, again

BioTrends Research Group releases Wave 2 report on AMAG's Feraheme

Walgreens re-launches its website with expanded shopping tools and services

Caldolor Injection effective in treating fever in hospitalized burn patients

FDA grants Fast Track designation for ARCA biopharma's Gencaro

Texas Court dismisses all claims against Merck in VIOXX-related lawsuit

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News